This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Review -
A locus on chromosome 20 encompassing genes that are
highly expressed in the epididymis
Åke Lundwall
Department of Laboratory Medicine, Lund University, Clinical Chemistry, University Hospital MAS, Malmö S-205 02,
Sweden
Abstract
During liquefaction of the ejaculate, the semen coagulum proteins semenogelin I (SEMG1) and semenogelin II
(SEMG2) are degraded to low molecular mass fragments by kallikrein-related peptidase 3 (KLK3), also known as
prostate-specific antigen. Semenogelin molecules initiate their own destruction by chelating
Zn2+ that normally would completely inhibit the proteolytic activity of KLK3. In a similar way, semenogelins might regulate the activity of
kallikrein-related peptidases in the epididymis, something that might be of importance for the maturation of
spermatozoa or generation of anti-bacterial peptides. Studies on the evolution of semen coagulum proteins have revealed that
most of them carry an exon that displays a rapid and unusual evolution. As a consequence, homologous proteins in
rodents and primates show almost no conservation in primary structure. Further studies on their evolution suggest
that the progenitor of the semen coagulum proteins probably was a protease inhibitor that might have displayed
antimicrobial activity. The semenogelin locus on chromosome 20 contains at least 17 homologous genes encoding
probable protease inhibitors with homology to semen coagulum proteins. All of these are highly expressed in the
epididymis where they, similar to the semenogelins, could affect the maturation of spermatozoa or display
antibacterial properties. (Asian J Androl 2007 July; 9: 540_544)
Keywords: antimicrobial; inhibitor; kunitz; proteolysis; semen; semenogelin; zinc; whey acidic protein four disulphide core
Correspondence to: Dr Åke Lundwall, Department of Laboratory Medicine, Lund University, Clinical Chemistry, University Hospital
MAS, Malmö S-205 02, Sweden.
Tel: +46-40-333-156 Fax: +46-40-929-023
E-mail: Ake.Lundwall@med.lu.se
DOI: 10.1111/j.1745-7262.2007.00303.x
1 Introduction
Following spermatogenesis, spermatozoa are transported through the tubular system of the epididymis, where
they acquire motility and fertilizing capability. The destination is the caudal part of the epididymis, which serves as a
reservoir of mature spermatozoa. During their transport and storage, spermatozoa are exposed to epididymal fluid
containing various components that could affect both the maturation process and provide protection against microbes.
At ejaculation, epididymal spermatozoa are transported through vas deferens and mixed with secretions of the
accessory sex glands. The ejaculatory mixing of human epididymal sperm and the fluids provided by the prostate and
the seminal vesicles gives rise to a semi-solid mass, known as the seminal coagulum. Within minutes, the seminal
coagulum liquefies to yield seminal plasma containing spermatozoa that now display propulsive motility. The major
structural components of the human seminal coagulum are semenogelin I (SEMG1) and semenogelin II (SEMG2),
which are both secreted at very high concentrations by the seminal vesicles [1, 2]. The semenogelins are also
synthesized in the secretory epithelium of the epididymis, but presumably in lower quantities than in the seminal
vesicles [3, 4]. During liquefaction, the semenogelins are degraded to peptide fragments by proteolytic enzymes.
The predominant semenogelin-degrading enzyme in semen is kallikrein-related peptidase 3 (KLK3), which is an
abundant protein secreted by the prostate gland, also known as prostate-specific antigen [5]. This review will address
the function of the semenogelins and describe the unique evolution of semen coagulum proteins, which have also led
to the discovery of a new locus of homologous genes expressed in the epididymis. The potential role in epididymal
biology of proteins expressed by genes from this locus
is also discussed.
2 Function of the semenogelins
Recent studies have cast new light on how the semenogelins might function during semen liquefaction
[6]. Studies on the enzymatic properties of KLK3 have
demonstrated that the protease is sensitive to
Zn2+ and that micromolar concentrations of the ion could inhibit
the proteolysis of chromogenic peptide substrate [7]. The
prostate secretion that delivers KLK3 to semen also
contains a high concentration of Zn2+ ions, which effectively
blocks the proteolytic activity of the enzyme. In seminal
plasma, the Zn2+ concentration of approximately
2 mmol/L would completely inhibit KLK3 and, therefore, prevent
semen liquefaction. The reason that semen liquefaction
still takes place is sequestration of
Zn2+ by seminal plasma proteins. The molecules that sequester the
Zn2+ are the semenogelins, as was concluded from experiments that
demonstrated that both SEMG1 and SEMG2 bind at least
10 molecules of Zn2+ each with an average affinity of
5 µmol/L [6]. Therefore, by chelating
Zn2, the semenogelins activates KLK3 and, thereby, initiate their own destruction.
The regulation of KLK3 by Zn2+ need not be
confined to semen liquefaction, as overlapping expression
of KLK3 and SEMG1 and SEMG2 has been demonstrated in several tissues [4, 8]. This suggests that the
semenogelins might function as general regulators of the
extracellular Zn2+ concentration, something that in turn
might affect proteolytic enzymes and other Zn-sensitive
molecules or biological systems. Among the potential
targets are 15 proteases, including KLK3, from the
kallikrein locus on the long arm of chromosome 19 [9_11].
Several of them have been shown to be sensitive to
Zn2+ and studies have clearly demonstrated that most of them
are expressed in the epididymis [8, 12]. It is reasonable
to believe that these enzymes are active during the
maturation of spermatozoa and that the semenogelins are
important as regulators of their activity. However, many
more studies are required to clarify the role of
Zn2+ and semenogelins in the modulation of these enzymes'
activities.
Another potential function of the epididymal
semenogelins could be in the innate immunity of the tissue. Peptide
fragments of semenogelins possess antibacterial activity,
which might be important as a defense mechanism both for
the epithelial cells and for the spermatozoa [13]. The latter is
presumably less likely, given the much higher semenogelin
concentration in seminal plasma that comes from the
seminal vesicle secretion.
3 Rapid evolution of semen coagulum proteins
Large parts of the semenogelins consist of repeats
of 60 amino acid residues. The repeats are poorly defined,
but owing to how well the overall structure is conserved,
they have been named type I, type II and type III repeats
[2]. Of these, the type I repeats are the most conserved.
In the common allelic variant of SEMG1 there are two
repeats of each type. SEMG2 is 79% similar in sequence
to SEMG1, but owing to two extra type I repeats, the
size of the molecule is 63 kDa compared with 50 kDa
for SEMG1 [1, 2]. Recently, a rare SEMG1 allele was
described, which is carried by 3_6% of the population in
both Europe and Japan [14, 15]. The novel allele is
lacking one type I repeat and gives rise to a smaller molecule
with a mass of 43 kDa.
Studies on primate semenogelins have revealed some
very interesting findings regarding their evolution. Most
conspicuous is the extension of semenogelin molecules
by species-specific additions of type I repeats (Figure 1).
In the chimpanzee and the orangutan this has created
very large SEMG1 molecules containing eight and nine
type I repeats [16, 17]. Similar duplications that extend
SEMG1 have also occurred in the gorilla, but in this
species there are frequent alleles that carry premature stop
codons that give rise to small SEMG1 molecules [16].
This type of evolution, with exon extension, is not
confined to apes and SEMG1, as SEMG2 from the rhesus
monkey, an Old World Monkey, contains six type I
repeats and the cotton-top tamarin, a New World Monkey,
carries five type I repeats in its SEMG1 [18, 19]. It has
been proposed that the extension of the molecules could
be the result of sexual selection caused by polyandry.
Species with promiscuous females, such as the chimpanzee tend to have large SEMG1 and perhaps produce
a firmer coagulum, which could function as a barrier
against spermatozoa from a second mating [17]. However, there is still no experimental evidence to
support this hypothesis and, therefore, it must be
considered as mere speculation.
The seminal vesicles of murine rodents (i.e. rats and
mice) secrete six proteins denoted SVS1_SVS6, at high
concentrations. Of these, SVS1 is related to copper amine
oxidases, such as histaminase, but because of substitutions
it is presumably enzymatically inactive [20]. The remaining
components, SVS2_SVS6, are homologous with the semenogelins in spite of very limited similarity at the amino
acid level [21]. However, the overall gene structure is
similar and consists of three exons separated by two
relatively short introns. The first exon codes for the signal
peptide and the two amino terminal residues of the
mature protein. The second exon codes for the remainder
of the secreted protein and also carries a few 3'
non-translated nucleotides. The third exon has no coding
nucleotides, but carries the poly-adenylation signal.
Studies have shown that the first and the third exons are
conserved between the semenogelin and the SVS genes,
whereas the second exon displays major differences,
which suggests rapid evolution. A comparison of the
second exon from SEMG1 and SVS2, also known as
semenoclotin, shows that the two termini of the exon
are conserved [22]. Therefore, both genes appear to
have evolved from a gene with a fairly small second exon
that has expanded in size since the separation of the murine
rodents and the primates (Figure 2). The reason for the
size expansion is duplications of repeats, which in the
primates are 180 bp and in the murine rodents are
between 21 and 39 bp [2, 20, 23]. SEMG2 and
SVS3 also seem to have evolved in this way. The second exons of
SVS4_SVS6 are smaller and have evolved in a different
manner owing to selection of a new splice site [20]. The
same mechanism also yields the unique structure of the
gene that codes for the polyprotein that after processing
yields three of the major proteins in guinea pig seminal
vesicle secretion [24]. Comparison of nucleotide
sequences shows that approximately 0.5 kb in the first
intron of the guinea pig gene and the second exon of
SEMG2 are conserved. Owing to mutation, the first
splice site, which is homologous with that in
SEMG2, is skipped and instead a second splice site located 4 360 bp
further downstream is used. This generates a new and
unique gene product in the guinea pig, which has no
similarity to either the semenogelins or SVS proteins.
4 Identification of a protease inhibitor locus
To identify additional genes with homology to the
semen coagulum proteins, sequence databases were searched using the conserved first exon of semenogelin
and SVS genes. It was discovered that the genes of
elafin (PI3) and secretory leukocyte proteinase inhibitor
(SLPI) are homologous to those of the semen coagulum
proteins [25]. As with the above described similarity
between different genes of semen coagulum proteins,
the similarity of the PI3 and SLPI genes to those of the
semen coagulum proteins is confined to the first and the
last exon. The translation product has no similarity at all
to any of the known semen coagulum proteins. Instead,
both elafin and SLPI carry the structural motif of whey
acidic protein four disulphide core (WFDC) domains. There
are two such domains in SLPI and one in elafin. The WFDC
domain binds and inhibits serine proteinases and both
elafin and SLPI are strong inhibitors of elastase, a serine
protease secreted by neutrophil granulocytes [26, 27].
Investigations into the chromosomal localization by
in situ hybridization had shown that the genes of
SEMG1, SEMG2 and PI3 were located in the same region on the
human chromosome 20q12-13.1 [28, 29]. When DNA sequences from the human genome project were made
available, it became clear that SLPI was also located close
to the semenogelin genes. This inspired a closer
inspection of the semenogelin locus for additional genes. In
this way, we first discovered a gene that was highly
expressed in the prostate and that also carried a WFDC
domain [30]. Eventually, 14 new genes that had between 1 and 4 WFDC domains were discovered at the
locus [31]. Three of the genes also encode kunitz
domains, another serine protease inhibitor domain, in
addition to the WFDC domains. Recently, we have also
identified 3 novel genes at the locus that carry a single
kunitz domain, but no WFDC domain (unpublished observation). In all, this increases the number of
functional protease inhibitor genes at the locus to 17 (Figure 3).
All the genes are basically organized as the
PI3 and SLPI genes, with one exon for the signal peptide, and one exon
for each protease inhibitor domain, followed by an exon
with 3' non-translated nucleotides that has no or very
little coding information.
5 Possible function of inhibitor molecules in the
epididymis
Studies on the expression of WFDC-encoding genes
show that several of them (e.g. PI3, SLPI, WFDC2,
WFDC3 and WFDC10B) are expressed in almost every
tissue, whereas others have a more restricted pattern of
expression [31]. All of them generate transcripts in the
epididymis and most of them also in the testis, with the
trachea as the third most common site of expression.
The presence of WFDC and Kunitz domains in the genes
suggests that they might function as inhibitors of locally
produced proteases, which could be either endogenous
in origin or the products of micro-organisms. Potential
endogenous target proteases are members of the kallikrein-related peptidases on chromosome 19, as was also
suggested above for the Zn2+/semenogelin system. Prime
candidate targets among exogenous proteases are serine
peptidases secreted by bacteria, which might serve as
virulence factors. However, the novel genes might also
have a direct toxic effect on micro-organisms, as there
are several reports showing that SLPI possesses
antimicrobial activity and that this property is independent of
the protease inhibitor function [32]. Therefore, it is
possible that the novel proteins are an important part of the
natural defense against infection.
Except for the information gained by studies on SLPI,
and to a lesser extent elafin, very little is known
regarding the function of other proteins from the locus. There
are a few scattered studies, which, among other things,
have shown that both human eppin and mouse WFDC12,
also named SWAM1, possess anti-bacterial activity and,
therefore, support the natural defense hypothesis [33,
34]. Why innate immunity should be so important in the
epididymis is harder to understand. Perhaps the
epididymis serves as the equivalent of a weapon store for the
spermatozoa, where they can arm themselves before they
encounter microorganisms in the female genital tract. This
is a very attractive idea, but definite answers have to
await future research into this new and interesting
aspect of epididymal function.
Acknowledgment
This work was supported by grants from Österlunds
trust, MAS cancer and the Medical Faculty at Lund University.
References
1 Lilja H, Abrahamsson PA, Lundwall Å. Semenogelin, the
predominant protein in human semen. Primary structure and
identification of closely related proteins in the male accessory sex glands
and on the spermatozoa. J Biol Chem 1989; 264: 1894_900.
2 Lilja H, Lundwall Å. Molecular cloning of epididymal and
seminal vesicular transcripts encoding a semenogelin-related protein.
Proc Natl Acad Sci U S A 1992; 89: 4559_63.
3 Bjartell A, Malm J, Möller C, Gunnarsson M, Lundwall Å, Lilja
H. Distribution and tissue expression of semenogelin I and II in
man as demonstrated by in situ hybridization and
immunocytochemistry. J Androl 1996; 17; 17_26.
4 Lundwall Å, Bjartell A, Olsson AY, Malm J. Semenogelin I and II,
the predominant human seminal plasma proteins, are also
expressed in non-genital tissues. Mol Hum Reprod 2002; 8: 805_10.
5 Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves
the predominant seminal vesicle protein. J Clin Inves 1985;
76: 1899_903.
6 Jonsson M, Linse S, Frohm B, Lundwall Å, Malm J. Semenogelins
I and II bind zinc and regulate the activity of prostate-specific
antigen. Biochem J 2005; 387: 447_53.
7 Malm J, Hellman J, Hogg P, Lilja H. Enzymatic action of
prostate-specific antigen (PSA or hK3), substrate specificity and regulation
by Zn2+, a tight-binding inhibitor. Prostate 2000; 45: 132_9.
8 Olsson AY, Bjartell A, Lilja H, Lundwall Å. Expression of
prostate-specific antigen (PSA) and human glandular kallikrein 2
(hK2) in ileum and other extraprostatic tissues. Int J Cancer
2005; 113: 290_7.
9 Gan L, Lee I, Smith R, Argonza-Barrett R, Lei H, McCuaig J,
et al. Sequencing and expression analysis of the serine protease
gene cluster located in chromosome 19q13 region. Gene 2000;
257: 119_30.
10 Harvey TJ, Hooper JD, Myers SA, Stephenson SA, Ashworth LK,
Clements JA. Tissue-specific expression patterns and fine
mapping of the human kallikrein (KLK) locus on proximal 19q13.4.
J Biol Chem 2000; 275: 37397_406.
11 Yousef GM, Chang A, Scorilas A, Diamandis EP. Genomic
organization of the human kallikrein gene family on chromosome
19q13.3-q13.4. Biochem Biophys Res Commun 2000; 276:
125_33.
12 Petraki CD, Papanastasiou PA, Karavana VN, Diamandis EP.
Cellular distribution of human tissue kallikreins,
immunohistochemical localization. Biol Chem 2006; 387: 653_63.
13 Bourgeon F, Evrard B, Brillard-Bourdet M, Colleu D, Jegou B,
Pineau C. Involvement of semenogelin-derived peptides in the
antibacterial activity of human seminal plasma. Biol Reprod
2004; 70: 768_74.
14 Lundwall Å, Giwercman A, Ruhayel Y, Giwercman Y, Lilja H,
Hallden C, et al. A frequent allele codes for a truncated variant of
semenogelin I, the major protein component of human semen
coagulum. Mol Hum Reprod 2003; 9: 345_50.
15 Miyano S, Yoshida K, Yoshiike M, Miyamoto C, Furuichi Y, Iwamoto
T. A large deletion of the repeat site in semenogelin I is not involved
in male infertility. Int J Mol Med 2003; 11: 435_40.
16 Jensen-Seaman MI, Li WH. Evolution of the hominoid semenogelin
genes, the major proteins of ejaculated semen. J Mol Evol 2003; 57:
261_70.
17 Kingan SB, Tatar M, Rand DM. Reduced polymorphism in the
chimpanzee semen coagulating protein, semenogelin I. J Mol
Evol 2003; 57: 159_69.
18 Lundwall Å. The cotton-top tamarin carries an extended
semenogelin I gene but no semenogelin II gene. Eur J Biochem
1998; 255: 45_51.
19 Ulvsbäck M, Lundwall Å. Cloning of the semenogelin II gene of
the rhesus monkey. Duplications of 360 bp extend the coding
region in man, rhesus monkey and baboon. Eur J Biochem 1997;
245: 25_31.
20 Lundwall Å, Malm J, Clauss A, Valtonen-Andre C, Olsson AY.
Molecular cloning of complementary DNA encoding mouse
seminal vesicle-secreted protein SVS I and demonstration of homology
with copper amine oxidases. Biol Reprod 2003; 69: 1923_30.
21 Lundwall Å, Lazure C. A novel gene family encoding proteins
with highly differing structure because of a rapidly evolving exon.
FEBS Letters 1995; 374: 53_6.
22 Lundwall Å. The cloning of a rapidly evolving
seminal-vesicle-transcribed gene encoding the major clot-forming protein of
mouse semen. Eur J Biochem 1996; 235: 424_30.
23 Harris SE, Harris MA, Johnson CM, Bean MF, Dodd JG, Matusik
RJ, et al. Structural characterization of the rat seminal vesicle
secretion II protein and gene. J Biol Chem 1991; 265: 9896_903.
24 Hagstrom JE, Fautsch MP, Perdok M, Vrabel A, Wieben ED.
Exons lost and found. Unusual evolution of a seminal vesicle
transglutaminase substrate. J Biol Chem 1996; 271: 21114_9.
25 Lundwall Å, Ulvsbäck M. The gene of the protease inhibitor
SKALP/elafin is a member of the REST gene family. Biochem
Biophys Res Commun 1996; 221: 323_7.
26 Thompson RC, Ohlsson K. Isolation, properties, and complete
amino acid sequence of human secretory leukocyte protease
inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl
Acad Sci USA 1986, 83: 6692_6.
27 Wiedow O, Schroder JM, Gregory H, Young JA, Christophers E.
Elafin, an elastase-specific inhibitor of human skin. Purification,
characterization, and complete amino acid sequence. J Biol Chem
1990; 265: 14791_5.
28 Molhuizen HO, Zeeuwen PL, Olde Weghuis D, Geurts van Kessel A,
Schalkwijk J. Assignment of the human gene encoding the
epidermal serine proteinase inhibitor SKALP (PI3) to chromosome
region 20q12_>q13. Cytogenet Cell Genet 1994; 66: 129_31.
29 Ulvsbäck M, Lazure C, Lilja H, Spurr NK, Rao VV, Loffler C,
et al. Gene structure of semenogelin I and II. The predominant
proteins in human semen are encoded by two homologous genes
on chromosome 20. J Biol Chem 1992; 267: 18080_4.
30 Lundwall Å, Clauss A. Identification of a novel protease
inhibitor gene that is highly expressed in the prostate. Biochem
Biophys Res Commun 2002; 290: 452_6.
31 Clauss A, Lilja H, Lundwall Å. A locus on human chromosome 20
contains several genes expressing protease inhibitor domains with
homology to whey acidic protein. Bioch J 2002; 368: 233_42.
32 Hiemstra PS. Novel roles of protease inhibitors in infection and
inflammation. Bioch Soc Trans 2002; 30: 116_20.
33 Hagiwara K, Kikuchi T, Endo Y, Huqun, Usui K, Takahashi M,
et al. Mouse SWAM1 and SWAM2 are antibacterial proteins
composed of a single whey acidic protein motif. J Immunol
2003; 170: 1973_9.
34 Yenugu S, Richardson RT, Sivashanmugam P, Wang Z, O'Rand
MG, French FS, et al. Antimicrobial activity of human EPPIN,
an androgen-regulated, sperm-bound protein with a whey acidic
protein motif. Biol Reprod 2004; 71: 1484_90. |